Titre : HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer
link : HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer
HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer
TGIF! Here's your HCV news with blog updates from around the web.
HCV Review
If you are interested in a weekly news recap start with HepCBC.
New At MD Magazine
A review of more than 1,000 studies found the vast majority of economic analyses of HCV therapies don’t incorporate patient input.
Worldwide HCV prevalence in 2017 dropped 2% from 2015 levels to 69.6 million viremic infections, thanks to increased treatment and prevention.
The fixed-dose combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) (Technivie, AbbVie), which is approved to treat HCV genotype 4, was combined with the pangenotypic DAA, sofosbuvir (SOF) (Sovaldi, Gilead), in addition to ribavirin for 12 weeks in patients having genotype 3 with cirrhosis, and with or without ribavirin in type 3 patients without cirrhosis. In addition, the regimen with ribavirin was administered for either 6 or 8 weeks to genotype 2 patients without cirrhosis.
New at Healio
Mavyret (glecaprevir/pibrentasvir), Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) and Liver cancer:
New at NATAP
"Eradication of HCV has been shown to reduce the risk of hepatocellular carcinoma, to improve liver fibrosis, and to decrease the risk of other complications of chronic liver disease (39). However, the effects of HCV eradication on the extrahepatic manifestations of HCV have not been well studied in the new era of DAAs. Our study supports the idea that HCV eradication leads to a reduction in HbA1c in patients with diabetes."
Liver Cancer
"Most HCV-infected patients in the United States will undergo DAA-based antiviral treatment in the next few years and the vast majority of them will achieve SVR. Our results suggest that DAA-induced SVR is associated with a 71% reduction in HCC risk (AHR 0.29, 95% CI 0.23-0.37) compared to treatment failure. The reduction in HCC risk associated with SVR was similar irrespective of whether SVR was achieved by DAA-ONLY, DAA+IFN or IFN-ONLY regimens. This suggests that eradication of HCV reduces HCC risk independently of how it is achieved. In contrast to prior reports that suggested an increased HCC risk in patients treated with DAAs[[3], [7]], we found that receipt of DAA-ONLY antiviral treatment was not associated with increased risk of HCC when compared to receipt of IFN-ONLY antiviral treatment.....We found no evidence that treatment with DAAs was associated with increased risk of HCC compared to treatment with IFN.
Medscape Medical News
Sofosbuvir Safe, Effective for HCV in Those With CKD
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.
Lower GI Reading Room
Integrated care in prison systems key to reducing rates, transmission risk post-release
Baby Boomers - New At HepatitisC.net
Out of 3.5 million Americans chronically infected with HCV, 80% are “baby boomers” (born between 1945 and 1965). If you were born between 1945 and 1952, you're now eligible for a senior citizen discount. Turning 65 does have its perks, especially grandchildren, right? If you're a grandparent living with the hepatitis C virus, Karen Hoyt, has a few tips for you; What to Tell Your Grandchild About Hepatitis C. Jump over to HepatitisC.net and view all blog updates, here.
HCV Stigma - New at HEP
HCV Stigma is in the spotlight over at Hep, Rick Nash, always positive, writes about stigma from a fresh prospective; Stigma: It’s not me, it’s you. In addition, "Science over Stigma explores the discriminatory, biased, and unnecessary practice of requiring a period of sobriety prior to receiving HCV curative treatment." Read the article, here.
Triaging Hepatitis C Treatment: Why the Fibrosis Score Is Not Valid, is a look at the bottom line results, what they mean for patients seeking treatment, written by devoted HCV advocate Greg Jefferys. Read additional blog articles at Hep, here.
Triaging Hepatitis C Treatment: Why the Fibrosis Score Is Not Valid, is a look at the bottom line results, what they mean for patients seeking treatment, written by devoted HCV advocate Greg Jefferys. Read additional blog articles at Hep, here.
October issue of Attitude
Gay men with hepatitis C are suffering stigma not seen since the HIV/Aids crisis, read the article published in the latest issue of Attitude.
Hepatitis B
Over at Hepatitis B Foundation is a three part series with easy to read information about the hepatitis B virus, last week part three was published: Part I is about how the virus is transmitted, and may have helped you determine how you were infected with HBV. In Part II we will discuss the people closest to you who may be susceptible to your infection. Part III is about preventing future transmission to others. View all blog updates, here.
In Case You Missed It
Enjoy the weekend!
Tina
Thus articles HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer
that is all articles HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer the link address https://newsaninpiration.blogspot.com/2017/09/hcv-tgif-patient-voice-lacking-in-hcv.html
0 Response to "HCV TGIF: Patient Voice Lacking in HCV Cost-effectiveness Research, Baby Boomers, and Liver Cancer"
Post a Comment